Report Detail

Medical Industry Global Long-Acting Monoclonal Antibodies Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • RnM4354212
  • |
  • 12 November, 2021
  • |
  • Global
  • |
  • 91 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Medical Industry

1 Market Overview

  • 1.1 Product Overview and Scope of Long-Acting Monoclonal Antibodies
  • 1.2 Classification of Long-Acting Monoclonal Antibodies by Type
    • 1.2.1 Overview: Global Long-Acting Monoclonal Antibodies Market Size by Type: 2020 Versus 2021 Versus 2026
    • 1.2.2 Global Long-Acting Monoclonal Antibodies Revenue Market Share by Type in 2020
    • 1.2.3 Murine Source
    • 1.2.4 Chimeric Source
    • 1.2.5 Human Source
  • 1.3 Global Long-Acting Monoclonal Antibodies Market by Application
    • 1.3.1 Overview: Global Long-Acting Monoclonal Antibodies Market Size by Application: 2020 Versus 2021 Versus 2026
    • 1.3.2 Cancer
    • 1.3.3 Autoimmune Diseases
    • 1.3.4 Inflammatory Diseases
    • 1.3.5 Infectious Diseases
    • 1.3.6 Others
  • 1.4 Global Long-Acting Monoclonal Antibodies Market Size & Forecast
  • 1.5 Global Long-Acting Monoclonal Antibodies Market Size and Forecast by Region
    • 1.5.1 Global Long-Acting Monoclonal Antibodies Market Size by Region: 2016 VS 2021 VS 2026
    • 1.5.2 Global Long-Acting Monoclonal Antibodies Market Size by Region, (2016-2021)
    • 1.5.3 North America Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
    • 1.5.4 Europe Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
    • 1.5.5 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
    • 1.5.6 South America Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
    • 1.5.7 Middle East and Africa Long-Acting Monoclonal Antibodies Market Size and Prospect (2016-2026)
  • 1.6 Market Drivers, Restraints and Trends
    • 1.6.1 Long-Acting Monoclonal Antibodies Market Drivers
    • 1.6.2 Long-Acting Monoclonal Antibodies Market Restraints
    • 1.6.3 Long-Acting Monoclonal Antibodies Trends Analysis

2 Company Profiles

  • 2.1 Eli Lilly
    • 2.1.1 Eli Lilly Details
    • 2.1.2 Eli Lilly Major Business
    • 2.1.3 Eli Lilly Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.1.4 Eli Lilly Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.1.5 Eli Lilly Recent Developments and Future Plans
  • 2.2 Abbott Laboratories
    • 2.2.1 Abbott Laboratories Details
    • 2.2.2 Abbott Laboratories Major Business
    • 2.2.3 Abbott Laboratories Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.2.4 Abbott Laboratories Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.2.5 Abbott Laboratories Recent Developments and Future Plans
  • 2.3 AstraZeneca
    • 2.3.1 AstraZeneca Details
    • 2.3.2 AstraZeneca Major Business
    • 2.3.3 AstraZeneca Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.3.4 AstraZeneca Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.3.5 AstraZeneca Recent Developments and Future Plans
  • 2.4 Amgen
    • 2.4.1 Amgen Details
    • 2.4.2 Amgen Major Business
    • 2.4.3 Amgen Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.4.4 Amgen Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.4.5 Amgen Recent Developments and Future Plans
  • 2.5 Bayer AG
    • 2.5.1 Bayer AG Details
    • 2.5.2 Bayer AG Major Business
    • 2.5.3 Bayer AG Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.5.4 Bayer AG Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.5.5 Bayer AG Recent Developments and Future Plans
  • 2.6 Johnson & Johnson
    • 2.6.1 Johnson & Johnson Details
    • 2.6.2 Johnson & Johnson Major Business
    • 2.6.3 Johnson & Johnson Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.6.4 Johnson & Johnson Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.6.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.7 Pfizer
    • 2.7.1 Pfizer Details
    • 2.7.2 Pfizer Major Business
    • 2.7.3 Pfizer Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.7.4 Pfizer Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.7.5 Pfizer Recent Developments and Future Plans
  • 2.8 GlaxoSmithKline
    • 2.8.1 GlaxoSmithKline Details
    • 2.8.2 GlaxoSmithKline Major Business
    • 2.8.3 GlaxoSmithKline Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.8.4 GlaxoSmithKline Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.8.5 GlaxoSmithKline Recent Developments and Future Plans
  • 2.9 Merck
    • 2.9.1 Merck Details
    • 2.9.2 Merck Major Business
    • 2.9.3 Merck Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.9.4 Merck Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.9.5 Merck Recent Developments and Future Plans
  • 2.10 Novartis
    • 2.10.1 Novartis Details
    • 2.10.2 Novartis Major Business
    • 2.10.3 Novartis Long-Acting Monoclonal Antibodies Product and Solutions
    • 2.10.4 Novartis Long-Acting Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2021)
    • 2.10.5 Novartis Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Long-Acting Monoclonal Antibodies Revenue and Share by Players (2019-2021)
  • 3.2 Market Concentration Rate
    • 3.2.1 Top 3 Long-Acting Monoclonal Antibodies Players Market Share
    • 3.2.2 Top 10 Long-Acting Monoclonal Antibodies Players Market Share
    • 3.2.3 Market Competition Trend
  • 3.3 Long-Acting Monoclonal Antibodies Players Head Office, Products and Services Provided
  • 3.4 Mergers & Acquisitions
  • 3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

  • 4.1 Global Long-Acting Monoclonal Antibodies Revenue and Market Share by Type (2016-2021)
  • 4.2 Global Long-Acting Monoclonal Antibodies Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

  • 5.1 Global Long-Acting Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
  • 5.2 Long-Acting Monoclonal Antibodies Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

  • 6.1 North America Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
  • 6.2 North America Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
  • 6.3 North America Long-Acting Monoclonal Antibodies Market Size by Country
    • 6.3.1 North America Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
    • 6.3.2 United States Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 6.3.3 Canada Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 6.3.4 Mexico Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

  • 7.1 Europe Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
  • 7.2 Europe Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
  • 7.3 Europe Long-Acting Monoclonal Antibodies Market Size by Country
    • 7.3.1 Europe Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
    • 7.3.2 Germany Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 7.3.3 France Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 7.3.4 United Kingdom Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 7.3.5 Russia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 7.3.6 Italy Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

  • 8.1 Asia-Pacific Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
  • 8.2 Asia-Pacific Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
  • 8.3 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region
    • 8.3.1 Asia-Pacific Long-Acting Monoclonal Antibodies Revenue by Region (2016-2026)
    • 8.3.2 China Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 8.3.3 Japan Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 8.3.4 South Korea Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 8.3.5 India Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 8.3.6 Southeast Asia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 8.3.7 Australia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

  • 9.1 South America Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
  • 9.2 South America Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
  • 9.3 South America Long-Acting Monoclonal Antibodies Market Size by Country
    • 9.3.1 South America Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
    • 9.3.2 Brazil Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 9.3.3 Argentina Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

  • 10.1 Middle East & Africa Long-Acting Monoclonal Antibodies Revenue by Type (2016-2026)
  • 10.2 Middle East & Africa Long-Acting Monoclonal Antibodies Revenue by Application (2016-2026)
  • 10.3 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country
    • 10.3.1 Middle East & Africa Long-Acting Monoclonal Antibodies Revenue by Country (2016-2026)
    • 10.3.2 Turkey Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 10.3.3 Saudi Arabia Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)
    • 10.3.4 UAE Long-Acting Monoclonal Antibodies Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

    12 Appendix

    • 12.1 Methodology
    • 12.2 Research Process and Data Source

    The Long-Acting Monoclonal Antibodies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

    According to our latest research, the global Long-Acting Monoclonal Antibodies size is estimated to be USD million in 2026 from USD million in 2020, with a change % between 2020 and 2021. The global Long-Acting Monoclonal Antibodies market size is expected to grow at a CAGR of % for the next five years.

    Market segmentation
    Long-Acting Monoclonal Antibodies market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

    Market segment by Type, covers
    Murine Source
    Chimeric Source
    Human Source

    Market segment by Application, can be divided into
    Cancer
    Autoimmune Diseases
    Inflammatory Diseases
    Infectious Diseases
    Others

    Market segment by players, this report covers
    Eli Lilly
    Abbott Laboratories
    AstraZeneca
    Amgen
    Bayer AG
    Johnson & Johnson
    Pfizer
    GlaxoSmithKline
    Merck
    Novartis

    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

    The content of the study subjects, includes a total of 12 chapters:
    Chapter 1, to describe Long-Acting Monoclonal Antibodies product scope, market overview, market opportunities, market driving force and market risks.
    Chapter 2, to profile the top players of Long-Acting Monoclonal Antibodies, with revenue, gross margin and global market share of Long-Acting Monoclonal Antibodies from 2019 to 2021.
    Chapter 3, the Long-Acting Monoclonal Antibodies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Long-Acting Monoclonal Antibodies market forecast, by regions, type and application, with revenue, from 2021 to 2026.
    Chapter 11 and 12, to describe Long-Acting Monoclonal Antibodies research findings and conclusion, appendix and data source.


    Summary:
    Get latest Market Research Reports on Long-Acting Monoclonal Antibodies. Industry analysis & Market Report on Long-Acting Monoclonal Antibodies is a syndicated market report, published as Global Long-Acting Monoclonal Antibodies Market 2021 by Company, Regions, Type and Application, Forecast to 2026. It is complete Research Study and Industry Analysis of Long-Acting Monoclonal Antibodies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,500.00
    $7,000.00
    2,628.50
    5,257.00
    3,094.00
    6,188.00
    395,570.00
    791,140.00
    262,780.00
    525,560.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report